Pharmaceuticals
2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy
Revolutionizing Treatments for Blood Cancers and Solid Tumors TAIPEI, June 16, 2026 /PRNewswire/ -- On June 16, the Tang Prize in Biopharmaceutical Science announced its 2026 laureates. Three leading scientists in the field of cellular immunotherapy, Drs. Steven A. Rosenberg, Michel Sadelain, an...
2026-06-16 20:30
910
Informa Markets and Thailand's Health Ministry Join Forces To Deliver a Successful Edition of International Healthcare Week 2026 in Bangkok
BANGKOK, June 16, 2026 /PRNewswire/ -- Informa Markets joins forces with Thailand's Department of Health Service Support (DHSS) to unveil International Healthcare Week 2026, a transformative regional healthcare platform that will elevate Thailand's position as a world-leading medical and wellness...
2026-06-16 12:24
3700
DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES
* Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia * 500,000-1 million people are estimated to be living with FSGS in the territories[1] * Dimerix eligible to ...
2026-06-16 10:53
7501
Halia Therapeutics Receives FDA Fast Track Designation for Ofirnoflast (HT-6184) in Lower-Risk Myelodysplastic Syndromes
Designation follows Phase 2 data showing durable transfusion independence and multilineage hematological improvement; full results presented at EHA2026 LEHI, Utah, June 15, 2026 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class therapie...
2026-06-15 20:00
3612
Kingworld Medicines Group (01110.HK) Signs MOU to Pursue Exclusive Distribution Rights for Two Lingnan Formula Products
Targeting Full-Channel Sales Coverage in Hong Kong, Mainland China and Cross-border E-commerce HONG KONG, June 15, 2026 /PRNewswire/ -- Kingworld Medicines Group Limited ("Kingworld Medicines" or the "Group", Stock Code: 01110.HK) announced that Morning Gold Medicine Company Limited ("Morning Go...
2026-06-15 13:08
6757
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
* The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for the combination arm vs 28% for the control arm at week 24. * Post-hoc analysis from the phase 3 SENTRY trial ...
2026-06-14 21:57
5145
Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.
BEIJING and BRIDGEWATER, N.J., June 12, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (hereinafter "Gan & Lee", stockcode: 603087.SH) announced that two of its core pipeline products in the fields of diabetes and obesity treatment have recently achieved positive clinical results. SUPER-3: Insul...
2026-06-12 20:00
7990
Frost & Sullivan: Global Pharmaceutical Industry Faces a High-Stakes Reset as AI, Biologics, and Supply Resilience Redefine Growth Through 2031
New Frost & Sullivan analysis reveals that future winners will be those that can execute faster, industrialise innovation, and navigate mounting pricing and geopolitical pressures LONDON, June 11, 2026 /PRNewswire/ -- Frost & Sullivan's latest analysis, Growth Opportunities in Global Pharmaceuti...
2026-06-11 04:56
3766
Servier and n-Lorem Foundation join forces to advance research in rare neurodevelopmental disorders
* Partnership will combine n-Lorem's cutting-edge antisense oligonucleotide (ASO) technology and Servier's R&D expertise with the aim of advancing ASO technology and delivering precision medicine approaches for patients across the world. * Servier strengthens its commitment to rare neurologic...
2026-06-10 16:00
4271
XtalPi Announces Strategic Partnership with a Leading Biopharma to Develop Oral Small Molecule Therapeutics for a GPCR Target
BOSTON and SHENZHEN, China, June 10, 2026 /PRNewswire/ -- XtalPi (2228.HK), a leading platform in artificial intelligence (AI) and robotics-driven drug discovery, today announced a strategic partnership with a prominent international biopharmaceutical company. The collaboration focuses on develo...
2026-06-10 10:00
5525
Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China
SHANGHAI and HONG KONG, June 10, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune di...
2026-06-10 09:00
5883
Lynk Pharmaceuticals' Partner Formation Bio Doses First Participant in Phase 1 Trial of BLKR201 (originally designated as LNK01006), a CNS-Penetrant TYK2 Inhibitor
HANGZHOU, China, SHANGHAI and BOSTON, June 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on autoimmune and inflammatory diseases, today announced a significant clinical milestone achieved by its globa...
2026-06-10 08:00
3748
Everest Medicines Enters into Exclusive Asia-Pacific Licensing Agreement with Vcare PharmaTech for Sumecigrel
SHANGHAI, June 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive ...
2026-06-09 08:21
5900
Dong Bang Co Ltd Strengthens Global Competitiveness with Advanced Veterinary Pharmaceuticals
SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- Dong Bang Co Ltd is strengthening its position in the global veterinary pharmaceutical market with high-value products including pet anesthetics and livestock reproductive hormones. Since its establishment in 1983, the company has specialized in m...
2026-06-08 13:00
3567
Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)
SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of positive topline results from its Phase II randomized, double-blind, placebo-controlled trial of CG2001 ...
2026-06-08 09:28
5372
Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize LNZ100 in Greater China
SHANGHAI, June 8, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an Asset Pur...
2026-06-08 08:55
9996
Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program
SAN DIEGO, June 8, 2026 /PRNewswire/ -- Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for Injection) and the appointment of Global Clinical Trials (GCT) as the lead contract research organization supporting international execution...
2026-06-08 08:30
4299
Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
HONG KONG, June 8, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes Association (ADA) 2026 Scientific Sessions (taking place June 5-8, 2026, in New Orleans, Louisiana), highlighting its differentiated portf...
2026-06-08 08:10
4802
Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
SHANGHAI and HONG KONG, June 8, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune di...
2026-06-08 08:00
5887
Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide
NEW ORLEANS, June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative therapies for metabolic diseases, today announced that key data from a head-to-head study (SLIMM...
2026-06-08 02:30
4052
Week's Top Stories
Most Reposted
MetaOptics Sharpens Focus on Metalens Commercialisation; Withdraws Nasdaq Listing Application, and Defers U.S. Dual Listing Plan
[Picked up by 313 media titles]
2026-08-07 22:30Thailand Ready to Welcome 191 Countries to the 2026 Annual Meetings of the International Monetary Fund and the World Bank Group
[Picked up by 301 media titles]
2026-08-06 15:10
GCash Parent Mynt Cited as Sole Philippine Firm in World's Top Fintech Companies List
[Picked up by 296 media titles]
2026-08-12 16:02
MetaOptics Ltd achieves 79% of FY2025 full-year revenue in 1H 2026, on track to fulfil purchase orders of key metalens production equipment in 2H 2026
[Picked up by 293 media titles]
2026-08-11 19:03Two CityUHK scholars elected to the European Academy of Engineering in recognition of their internationally acclaimed research achievements
[Picked up by 292 media titles]
2026-08-10 19:12
Most Read
Thailand Ready to Welcome 191 Countries to the 2026 Annual Meetings of the International Monetary Fund and the World Bank Group
2026-08-06 15:10
16243
AMTD IDEA's Receipt of NYSE Letter Regarding ADS Trading Price's Below Compliance Standards
2026-08-08 04:01
10080
China Yuchai International Announces Unaudited 2026 First Half-Year Financial Results
2026-08-07 18:00
9953